Pretraga rezultata za izvrsnost 2025




IBI: AN457; Milica Pešić***, naučni savetnik, Univerzitet u Beogradu, Institut za biološka istraživanja 'Siniša Stanković'; Polje: prirodno-matematičke i medicinske nauke; Period: 2020-2024;


eNauka profil: rp08606; ORCID: 0000-0002-9045-8239;


WOS indikatori: NR = 121; TC = 2359; HIndex = 28;


eNauka WOS indikatori: NR = 137; TC = 2361; HIndex = 29 ;


Lista A broj bodova: 324.7022 (552) 4.0%; Lista B broj bodova: 1373.4959 (552) 10.7%; Lista C broj bodova: 0.000 (0) nan%; Lista A broj bodova kolaboracije: 0.00312 (373) 83.6%; Lista B broj bodova kolaboracije: 10.00115 (373) 30.8%;

Statistika svih rezultata

StatistikaUkupno2013-20242015-20242018-20242020-2024
Broj rezultata12197846442
Broj citata23591899
Broj M bodova411.00411411.00411
Normirani broj citata1725.041373.49
Normirani broj M bodova rezultata kategorije M21a++M21a+M21+M22+M23+M24324.70324.70324.70324.70
Normirani broj M bodova rezultata kategorije M11+M12+M13+M14+M410.000.000.000.00
Normirani broj M bodova rezultata kategorije M11+M12+M13+M14+M41+M420.000.000.000.00
Normirani broj M bodova rezultata kategorije M510.000.000.000.00
Normirani broj M bodova rezultata kategorije M43+M440.000.000.000.00

Statistika rezultata nastalih u medunarodnim kolaboracijama

StatistikaUkupno2013-20242015-20242018-20242020-2024
Broj rezultata sa 20 i više autora11110
Broj citata rezultata sa 20 i više autora3936
Broj M bodova rezultata M21a++M21a+M21+M22+M23 sa 20 i više autora0.0000.000
Normirani broj citata rezultata sa 20 i više autora10.8310.00
Normirani broj M bodova rezultata M21a++M21a+M21+M22+M23 sa 20 i više autora0.000.00

Rezultati

RBIBIGodinaKatTipVrstaReferencaTCTCPBANBBNTCNaslovAutori
1.AN4572000ENUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS Vol. 19 (5-6): # 963 - 975 (13), (DOI: 10.1080/15257770008033036) 2000WOS121601.0000Inhibition of cell growth and proliferation in human glioma cells and normal human astrocytes induced by 8-Cl-cAMP and tiazofurinPesic M, Drabek K, Esler C, Ruzdijic S, Pejanovic V, Pietrzkowski Z
2.AN4572000EANTI-CANCER DRUGS Vol. 11 (9): # 765 - 770 (6), (DOI: 10.1097/00001813-200010000-00014) OCT 2000WOS113703.00008-Cl-cAMP and tiazofurin affect vascular endothelial growth factor production and glial fibrillary acidic protein expression in human glioblastoma cellsDrabek K, Pesic M, Piperski V, Ruzdijic S, Medic-Mijacevic L, Pietrzkowski Z, Rakic L
3.AN4572001EJUGOSLOVENSKA MEDICINSKA BIOHEMIJA-YUGOSLAV MEDICAL BIOCHEMISTRY Vol. 20 (1): # 9 - 18 (10), (DOI: ) JAN-MAR 2001WOS511100.5556Downregulation of c-fos and c-myc expression and apoptosis induction by tiazofurin and 8-Cl-cAMP in human melanoma cellsRuzdijic S, Milosevic J, Popovic N, Pesic M, Stojilkovic M, Kanazir S, Todorovic D, Ristic-Fira A, Krstic-Demonacos M, Kanazir D, Rakic L
4.AN4572006EINVESTIGATIONAL NEW DRUGS Vol. 24 (1): # 15 - 25 (11), (DOI: 10.1007/s10637-005-4539-8) JAN 2006WOS90700.0000The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitroJankovic D, Pesic M, Markovic J, Kanazir S, Markovic I, Rakic L, Ruzdijic S
5.AN4572006EJOURNAL OF CHEMOTHERAPY Vol. 18 (1): # 66 - 73 (8), (DOI: 10.1179/joc.2006.18.1.66) FEB 2006WOS90537053.0000Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugsPesic M, Markovic J, Jankovic D, Kanazir S, Markovic I, Rakic L, Ruzdijic S
6.AN4572006ENEUROBIOLOGICAL STUDIES - FROM GENES TO BEHAVIOUR 2006 Vol. (): # 1 - 19 (19), (DOI: ) 2006WOS00500.0000The role of genetic instability in the development of the multidrug resistance phenotype in brain tumorsRuzdijic S, Pesic M, Kanazir S, Rakie L, Tanic N
7.AN4572008ECANCER BIOLOGY & THERAPY Vol. 7 (7): # 1024 - 1032 (9), (DOI: 10.4161/cbt.7.7.6036) JUL 2008WOS48316031.0000Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R)Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic I, Ruzdijic S
8.AN4572009EINVESTIGATIONAL NEW DRUGS Vol. 27 (2): # 99 - 110 (12), (DOI: 10.1007/s10637-008-9140-5) APR 2009WOS82602.0000Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R)Pesic M, Andjelkovic T, Bankovic J, Markovic I, Rakic L, Ruzdijic S
9.AN4572010EINVESTIGATIONAL NEW DRUGS Vol. 28 (4): # 482 - 492 (11), (DOI: 10.1007/s10637-009-9277-x) AUG 2010WOS61401.0000Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamilPesic M, Podolski A, Rakic L, Ruzdijic S
10.AN4572011EBIOMEDICINE & PHARMACOTHERAPY Vol. 65 (5): # 345 - 353 (9), (DOI: 10.1016/j.biopha.2011.04.015) AUG 2011WOS68486048.0000The role of paclitaxel in the development and treatment of multidrug resistant cancer cell linesPodolski-Renic A, Andelkovic T, Bankovic J, Tanic N, Ruzdijic S, Pesic M
11.AN4572011EFOOD AND CHEMICAL TOXICOLOGY Vol. 49 (12): # 3165 - 3173 (9), (DOI: 10.1016/j.fct.2011.09.035) DEC 2011WOS292412012.0000New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroidesPesic M, Bankovic J, Aljancic I, Todorovic N, Jadranin M, Vajs V, Tekvic V, Vuckovic I, Momcilovic M, Markovic I, Tanic N, Ruzdijic S
12.AN4572011EJOURNAL OF NATURAL PRODUCTS Vol. 74 (7): # 1613 - 1620 (8), (DOI: 10.1021/np200241c) JUL 2011WOS524013018.1818Isolation and Biological Evaluation of Jatrophane Diterpenoids from Euphorbia dendroidesAljancic I, Pesic M, Milosavljevic S, Todorovic N, Jadranin M, Miosavljevic G, Povrenovic D, Bankovic J, Tanic N, Markovic I, Ruzdijic S, Vajs V, Tesevic V
13.AN4572011ECANCER BIOMARKERS Vol. 10 (6): # 277 - 286 (10), (DOI: 10.3233/CBM-2012-0257) 2011WOS85804.1667Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patientsAndjelkovic T, Bankovic J, Milosevic Z, Stojsic J, Milinkovic V, Pesic M, Ruzdijic S, Tanic N
14.AN4572012EEXPERIMENTAL AND MOLECULAR PATHOLOGY Vol. 93 (2): # 200 - 206 (7), (DOI: 10.1016/j.yexmp.2012.05.010) OCT 2012WOS22161208.0000Genomic instability and p53 alterations in patients with malignant gliomaMilinkovic V, Bankovic J, Rakic M, Milosevic N, Stankovic T, Jokovic M, Milosevic Z, Skender-Gazibara M, Podolski-Renic A, Pesic M, Ruzdijic S, Tanic N
15.AN4572013ECANCER CHEMOTHERAPY AND PHARMACOLOGY Vol. 72 (3): # 683 - 697 (15), (DOI: 10.1007/s00280-013-2247-1) SEP 2013WOS373313015.0000Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testingPodolski-Renic A, Jadranin M, Stankovic T, Bankovic J, Stojkovic S, Chiourea M, Aljancic I, Vajs V, Tesevic V, Ruzdijic S, Gagos S, Tanic N, Pesic M
16.AN4572013EJOURNAL OF MOLECULAR STRUCTURE Vol. 1040 (): # 216 - 220 (5), (DOI: 10.1016/j.molstruc.2013.03.013) MAY 22 2013WOS16159010.7143Synthesis, characterization and cytotoxicity of a new palladium(II) complex with a coumarin-derived ligand. Crystal structure of 4-hydroxy-3-(1-(p-tolylimino)ethyl)-2H-chromen-2-one-palladium(II) complexJevtic V, Pesic M, Radic G, Vukovic N, Sukdolak S, Klisuric O, Podolski-Renic A, Tanic N, Trifunovic S
17.AN4572013EPHYTOCHEMISTRY Vol. 86 (): # 208 - 217 (10), (DOI: 10.1016/j.phytochem.2012.09.003) FEB 2013WOS393511019.4444Jatrophane diterpenoids from the latex of Euphorbia dendroides and their anti-P-glycoprotein activity in human multi-drug resistant cancer cell linesJadranin M, Pesic M, Aljancic I, Milosavljevic S, Todorovic N, Podolski-Renic A, Bankovic J, Tanic N, Markovic I, Vajs V, Tesevic V
18.AN4572013EPHYTOCHEMISTRY LETTERS Vol. 6 (2): # 246 - 252 (7), (DOI: 10.1016/j.phytol.2013.02.006) MAY 2013WOS44398032.5000Cytotoxic activity of sesquiterpene lactones from Inula britannica on human cancer cell linesFischedick J, Pesic M, Podolski-Renic A, Bankovic J, de V, Peric M, Todorovic S, Tanic N
19.AN4572013EEXPERIMENTAL CELL RESEARCH Vol. 319 (7): # 1013 - 1027 (15), (DOI: 10.1016/j.yexcr.2012.12.017) APR 15 2013WOS342610016.2500The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: The unique way of multi-drug resistance modulationBankovic J, Andrä J, Todorovic N, Podolski-Renic A, Milosevic Z, Miljkovic D, Krause J, Ruzdijic S, Tanic N, Pesic M
20.AN4572013EPLOS ONE Vol. 8 (1): #e54044 - (15), (DOI: 10.1371/journal.pone.0054044) JAN 11 2013WOS19189012.8571Purine Nucleoside Analog - Sulfinosine Modulates Diverse Mechanisms of Cancer Progression in Multi-Drug Resistant Cancer Cell LinesDacevic M, Isakovic A, Podolski-Renic A, Isakovic A, Stankovic T, Milosevic Z, Rakic L, Ruzdijic S, Pesic M
21.AN4572013EJOURNAL OF MEDICAL BIOCHEMISTRY Vol. 32 (4): # 406 - 416 (11), (DOI: 10.2478/jomb-2013-0050) OCT 2013WOS221101.1111NO-MODIFIED SAQUINAVIR IS EQUALLY EFFICIENT AGAINST DOXORUBICIN SENSITIVE AND RESISTANT NON-SMALL CELL LUNG CARCINOMA CELLSMijatovic S, Pesic M, Mojic M, Bankovic J, Miljkovic D, Fagone P, Mangano K, Nicoletti F, McCubrey J, Tanic N, Maksimovic-Ivanic D
22.AN4572014ECHEMMEDCHEM Vol. 9 (5): # 973 - 983 (11), (DOI: 10.1002/cmdc.201400044) MAY 2014WOS343312016.5000Discovery of 14-3-3 Protein- Protein Interaction Inhibitors that Sensitize Multidrug- Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693Mori M, Vignaroli G, Cau Y, Dinic J, Hill R, Rossi M, Colecchia D, Pesic M, Link W, Chiariello M, Ottmann C, Botta M
23.AN4572014EPHYTOCHEMISTRY Vol. 97 (): # 46 - 54 (9), (DOI: 10.1016/j.phytochem.2013.11.001) JAN 2014WOS373211017.7778Diarylheptanoids from the bark of black alder inhibit the growth of sensitive and multi-drug resistant non-small cell lung carcinoma cellsNovakovic M, Pesic M, Trifunovic S, Vuckovic I, Todorovic N, Podolski-Renic A, Dinic J, Stojkovic S, Tesevic V, Vajs V, Milosavljevic S
24.AN4572014EPHYTOCHEMISTRY Vol. 98 (): # 190 - 196 (7), (DOI: 10.1016/j.phytochem.2013.11.025) FEB 2014WOS282710016.8750Two structurally distinct chalcone dimers from Helichrysum zivojinii and their activities in cancer cell linesAljancic I, Vuckovic I, Jadranin M, Pesic M, Dordevic I, Podolski-Renic A, Stojkovic S, Menkovic N, Vajs V, Milosavljevic S
25.AN4572014ETRANSLATIONAL RESEARCH Vol. 164 (5): # 411 - 423 (13), (DOI: 10.1016/j.trsl.2014.06.005) NOV 2014WOS47429030.0000Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinomaMilosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, Dzodic R, Tanic N, Bankovic J
26.AN4572014EMETABOLIC ENGINEERING Vol. 23 (): # 145 - 153 (9), (DOI: 10.1016/j.ymben.2014.03.005) MAY 2014WOS686011033.3333Elucidation and in planta reconstitution of the parthenolide biosynthetic pathwayLiu Q, Manzano D, Tanic N, Pesic M, Bankovic J, Pateraki I, Ricard L, Ferrer A, de V, van d, Bouwmeester H
27.AN4572014EPLANTA MEDICA Vol. 80 (13): # 1088 - 1096 (9), (DOI: 10.1055/s-0034-1382993) AUG 2014WOS18159010.7143Antioxidative Activity of Diarylheptanoids from the Bark of Black Alder (Alnus glutinosa) and Their Interaction with Anticancer DrugsDinic J, Novakovic M, Podolski-Renic A, Stojkovic S, Mandic B, Tesevic V, Vajs V, Isakovic A, Pesic M
28.AN4572015ECANCER CHEMOTHERAPY AND PHARMACOLOGY Vol. 76 (3): # 555 - 565 (11), (DOI: 10.1007/s00280-015-2821-9) SEP 2015WOS18151009.3750Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivativesStankovic T, Dankó B, Martins A, Dragoj M, Stojkovic S, Isakovic A, Wang H, Wu Y, Hunyadi A, Pesic M
29.AN4572015ETUMOR BIOLOGY Vol. 36 (11): # 8773 - 8780 (8), (DOI: 10.1007/s13277-015-3620-y) NOV 2015WOS15147014.0000Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcomeDragoj M, Milosevic Z, Bankovic J, Dinic J, Pesic M, Tanic N, Stankovic T
30.AN4572015ECHEMICO-BIOLOGICAL INTERACTIONS Vol. 232 (): # 85 - 93 (9), (DOI: 10.1016/j.cbi.2015.03.013) MAY 5 2015WOS13311313051.3636Anti-cancer effects of cerium oxide nanoparticles and its intracellular redox activityPesic M, Podolski-Renic A, Stojkovic S, Matovic B, Zmejkoski D, Kojic V, Bogdanovic G, Pavicevic A, Mojovic M, Savic A, Milenkovic I, Kalauzi A, Radotic K
31.AN4572015EFITOTERAPIA Vol. 105 (): # 169 - 176 (8), (DOI: 10.1016/j.fitote.2015.07.003) SEP 2015WOS15147014.0000Chemo-protective and regenerative effects of diarylheptanoids from the bark of black alder (Alnus glutinosa) in human normal keratinocytesDinic J, Randelovic T, Stankovic T, Dragoj M, Isakovic A, Novakovic M, Pesic M
32.AN4572015EEXPERIMENTAL CELL RESEARCH Vol. 335 (2): # 248 - 257 (10), (DOI: 10.1016/j.yexcr.2015.05.018) JUL 15 2015WOS181710010.6250Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicinStojkovic S, Podolski-Renic A, Dinic J, Stankovic T, Bankovic J, Hadzic S, Paunovic V, Isakovic A, Tanic N, Pesic M
33.AN4572015ECURRENT PHARMACEUTICAL DESIGN Vol. 21 (38): # 5589 - 5604 (16), (DOI: 10.2174/1381612821666151002113546) 2015WOS39365036.0000New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in CancerDinic J, Podolski-Renic A, Stankovic T, Bankovic J, Pesic M
34.AN4572016EBULLETIN OF MATHEMATICAL BIOLOGY Vol. 78 (6): # 1218 - 1237 (20), (DOI: 10.1007/s11538-016-0182-0) JUN 2016WOS109709.0000Transfer of Drug Resistance Characteristics Between Cancer Cell Subpopulations: A Study Using Simple Mathematical ModelsDurán M, Podolski-Renic A, Alvarez-Arenas A, Dinic J, Belmonte-Beitia J, Pesic M, Pérez-García V
35.AN4572016ECHEMICO-BIOLOGICAL INTERACTIONS Vol. 249 (): # 36 - 45 (10), (DOI: 10.1016/j.cbi.2016.02.019) APR 5 2016WOS86706.0000Structural differences in diarylheptanoids analogues from Alnus viridis and Alnus glutinosa influence their activity and selectivity towards cancer cellsDinic J, Novakovic M, Podolski-Renic A, Vajs V, Tesevic V, Isakovic A, Pesic M
36.AN4572016EEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY Vol. 118 (): # 107 - 120 (14), (DOI: 10.1016/j.ejmech.2016.04.011) AUG 8 2016WOS86706.0000Simple avarone mimetics as selective agents against multidrug resistant cancer cellsJeremic M, Pesic M, Dinic J, Bankovic J, Novakovic I, Segan D, Sladic D
37.AN4572016EMEDCHEMCOMM Vol. 7 (12): # 2265 - 2281 (17), (DOI: 10.1039/c6md00391e) 2016WOS21601.0000Mutual regulation and targeting of multidrug resistance and cancer stem phenotypePodolski-Renic A, Milosevic Z, Dinic J, Stankovic T, Bankovic J, Pesic M
38.AN4572016ECURRENT CANCER DRUG TARGETS Vol. 16 (3): # 226 - 237 (12), (DOI: 10.2174/1568009616666151113120705) 2016WOS35333033.0000Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line ModelsXavier C, Pesic M, Vasconcelos M
39.AN4572016EMOLECULES Vol. 21 (7): #843 - (16), (DOI: 10.3390/molecules21070843) JUL 2016WOS1191005.6250Resistance to DNA Damaging Agents Produced Invasive Phenotype of Rat Glioma Cells-Characterization of a New in Vivo ModelStojkovic S, Podolski-Renic A, Dinic J, Pavkovic Z, Ayuso J, Fernández L, Ochoa I, Pérez-García V, Pesic V, Pesic M
40.AN4572017ETRANSGENESIS AND SECONDARY METABOLISM Vol. (): # 205 - 230 (26), (DOI: 10.1007/978-3-319-28669-3_5) 2017WOS00600.0000Secondary Metabolite Profile of Transgenic Centaury (Centaurium erythraea Rafn.) Plants, Potential Producers of Anticancer CompoundsTrifunovic-Momcilov M, Krstic-Milosevic D, Trifunovic S, Podolski-Renic A, Pesic M, Subotic A
41.AN4572017EHISTOCHEMISTRY AND CELL BIOLOGY Vol. 148 (5): # 529 - 544 (16), (DOI: 10.1007/s00418-017-1590-4) NOV 2017WOS14146014.0000Targeting autophagy to modulate cell survival: a comparative analysis in cancer, normal and embryonic cellsRankov A, Ljujic M, Petric M, Radojkovic D, Pesic M, Dinic J
42.AN4572017EINVESTIGATIONAL NEW DRUGS Vol. 35 (6): # 718 - 732 (15), (DOI: 10.1007/s10637-017-0494-4) DEC 2017WOS98708.0000Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressorsDragoj M, Bankovic J, Sereti E, Stojanov S, Dimas K, Pesic M, Stankovic T
43.AN4572017ECELLULAR ONCOLOGY Vol. 40 (1): # 47 - 62 (16), (DOI: 10.1007/s13402-016-0304-6) FEB 2017WOS42386038.0000Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinomaDragoj M, Milosevic Z, Bankovic J, Tanic N, Pesic M, Stankovic T
44.AN4572017EEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES Vol. 105 (): # 159 - 168 (10), (DOI: 10.1016/j.ejps.2017.05.011) JUL 15 2017WOS231910011.8750DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cellsPodolski-Renic A, Bankovic J, Dinic J, Ríos-Luci C, Fernandes M, Ortega N, Kovacevic-Grujicic N, Martín V, Padrón J, Pesic M
45.AN4572017ESCIENTIFIC REPORTS Vol. 7 (): #44541 - (17), (DOI: 10.1038/srep44541) MAR 17 2017WOS696112030.5000Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesiclesLopes-Rodrigues V, Di L, Mleczko J, Meleady P, Henry M, Pesic M, Cabrera D, van L, Lima R, O'Connor R, Falcon-Perez J, Vasconcelos M
46.AN4572017EMETALLOMICS Vol. 9 (8): # 1132 - 1141 (10), (DOI: 10.1039/c7mt00183e) AUG 1 2017WOS38377037.0000Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxelPodolski-Renic A, Bosze S, Dinic J, Kocsis L, Hudecz F, Csampai A, Pesic M
47.AN4572017EJOURNAL OF GLOBAL HEALTH Vol. 7 (2): #020304 - (5), (DOI: 10.7189/jogh.07.020304) DEC 2017WOS28221806.8750Biodiversity, drug discovery, and the future of global health: Introducing the biodiversity to biomedicine consortium, a call to actionNeergheen-Bhujun V, Awan A, Baran Y, Bunnefeld N, Chan K, Dela C, Egamberdieva D, Elsässer S, Johnson M, Komai S, Konevega A, Malone J, Mason P, Nguon R, Piper R, Shrestha U, Pesic M, Kagansky A
48.AN4572018ECELLULAR ONCOLOGY Vol. 41 (4): # 409 - 426 (18), (DOI: 10.1007/s13402-018-0380-x) AUG 2018WOS242212011.0000Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinomaMilosevic Z, BankoviAç J, DiniAç J, Tsimplouli C, Sereti E, Dragoj M, PaunoviAç V, MilovanoviAç Z, StepanoviAç M, TaniAç N, Dimas K, PeiAç M
49.AN4572018EPHYTOCHEMISTRY Vol. 148 (): # 104 - 112 (9), (DOI: 10.1016/j.phytochem.2018.01.016) APR 2018WOS21197019.0000Jatrophane diterpenoids with multidrug-resistance modulating activity from the latex of Euphorbia nicaeensisKrstic G, Jadranin M, Todorovic N, Pesic M, Stankovic T, Aljancic I, Tesevic V
50.AN4572018ERADIOTHERAPY AND ONCOLOGY Vol. 128 (2): # 236 - 244 (9), (DOI: 10.1016/j.radonc.2018.04.033) AUG 2018WOS21181905.2941Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomideFrontiñán-Rubio J, Santiago-Mora R, Nieva-Velasco C, Ferrín G, Martínez-González A, Gómez M, Moreno M, Ariza J, Lozano E, Arjona-Gutiérrez J, Gil-Agudo A, De l, Pesic M, Peinado J, Villalba J, Pérez-Romasanta L, Pérez-García V, Alcaín F, Durán-Prado M
51.AN4572018EACTA BIOLOGICA HUNGARICA Vol. 69 (4): # 395 - 410 (16), (DOI: 10.1556/018.69.2018.4.3) DEC 2018WOS31701.0000COMPARATIVE TOXICITY EVALUATION OF TARGETED ANTICANCER THERAPEUTICS IN EMBRYONIC ZEBRAFISH AND SEA URCHIN MODELSBabic T, Dinic J, Buric S, Hadzic S, Pesic M, Radojkovic D, Rankov A
52.AN4572018EEUROPEAN JOURNAL OF HORTICULTURAL SCIENCE Vol. 83 (6): # 374 - 381 (8), (DOI: 10.17660/eJHS.2018/83.6.5) DEC 2018WOS54604.0000Effects of soil properties and fertilization on quality and biological activity of Swiss chardTopalovic A, Knezevic M, Trifunovic S, Novakovic M, Pesic M, Durovic D
53.AN4572018ECURRENT PHARMACEUTICAL DESIGN Vol. 24 (36): # 4334 - 4354 (21), (DOI: 10.2174/1381612825666190112164211) 2018WOS21194019.0000Potential of Natural-Based Anticancer Compounds for P-Glycoprotein InhibitionDinic J, Podolski-Renic A, Jeremic M, Pesic M
54.AN4572018EJOURNAL OF THE SERBIAN CHEMICAL SOCIETY Vol. 83 (11): # 1193 - 1207 (15), (DOI: 10.2298/JSC180627062J) 2018WOS32702.0000Alkylamino and aralkylamino derivatives of avarone and its mimetic as selective agents against non-small cell lung cancer cells, their antibacterial and antifungal potentialJeremic M, Dinic J, Pesic M, Stepanovic M, Novakovic I, Segan D, Sladic D
55.AN4572018EFUTURE MEDICINAL CHEMISTRY Vol. 10 (10): # 1177 - 1189 (13), (DOI: 10.4155/fmc-2017-0239) MAY 2018WOS22211707.0000Anticancer properties of the abietane diterpene 6,7-dehydroroyleanone obtained by optimized extractionGarcia C, Silva C, Monteiro C, Nicolai M, Viana A, Andrade J, Barasoain I, Stankovic T, Quintana J, Hernández I, González I, Estévez F, Díaz-Lanza A, Reis C, Afonso C, Pesic M, Rijo P
56.AN4572019EDRUG RESISTANCE UPDATES Vol. 46 (): #100643 - (25), (DOI: 10.1016/j.drup.2019.100643) SEP 2019WOS66585058.0000What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the icebergAlexa-Stratulat T, Pesic M, Gasparovic A, Trougakos I, Riganti C
57.AN4572019EEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY Vol. 181 (): #111580 - (14), (DOI: 10.1016/j.ejmech.2019.111580) NOV 1 2019WOS222112010.5000Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapyJovanovic M, Zhukovsky D, Podolski-Renic A, Domraceva I, Zalubovskis R, Sencanski M, Glisic S, Sharoyko V, Tennikova T, Dar'in D, Pesic M, Krasavin M
58.AN4572019EEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES Vol. 138 (): #105012 - (9), (DOI: 10.1016/j.ejps.2019.105012) OCT 1 2019WOS25238019.1667Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistancePodolski-Renic A, Dinic J, Stankovic T, Jovanovic M, Ramovic A, Pustenko A, Zalubovskis R, Pesic M
59.AN4572019EJOURNAL OF ETHNOPHARMACOLOGY Vol. 240 (): #111951 - (10), (DOI: 10.1016/j.jep.2019.111951) AUG 10 2019WOS19157015.0000Potential of Teucrium chamaedrys L. to modulate apoptosis and biotransformation in colorectal carcinoma cellsMilutinovic M, Maksimovic V, Cvetkovic D, Nikodijevic D, Stankovic M, Pesic M, Markovic S
60.AN4572019EJOURNAL OF MEDICINAL CHEMISTRY Vol. 62 (3): # 1657 - 1668 (12), (DOI: 10.1021/acs.jmedchem.8b01994) FEB 14 2019WOS292613011.8182Antioxidant-Inspired Drug Discovery: Antitumor Metabolite Is Formed in Situ from a Hydroxycinnamic Acid Derivative upon Free-Radical ScavengingFási L, Di M, Kuo C, Buric S, Martins A, Kúsz N, Béni Z, Dékány M, Balogh G, Pesic M, Wang H, Trouillas P, Hunyadi A
61.AN4572019EACS OMEGA Vol. 4 (5): # 8094 - 8103 (10), (DOI: 10.1021/acsomega.9b00512) MAY 2019WOS342911016.1111Cytotoxic Activity of Royleanone Diterpenes from Plectranthus madagascariensis BenthMatias D, Nicolai M, Saraiva L, Pinheiro R, Faustino C, Lanza A, Reis C, Stankovic T, Dinic J, Pesic M, Rijo P
62.AN4572019ESCIENTIFIC REPORTS Vol. 9 (): #9332 - (13), (DOI: 10.1038/s41598-019-45863-z) JUN 27 2019WOS31275027.0000Interplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in CancerAlvarez-Arenas A, Podolski-Renic A, Belmonte-Beitia J, Pesic M, Calvo G
63.AN4572019EJOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY Vol. 34 (1): # 665 - 671 (7), (DOI: 10.1080/14756366.2019.1575372) JAN 1 2019WOS66904.2857Design, synthesis, and biological evaluation of novel derivatives of dithiodiglycolic acid prepared via oxidative coupling of thiolsBakulina O, Bannykh A, Jovanovic M, Domraceva I, Podolski-Renic A, Zalubovskis R, Pesic M, Dar'in D, Krasavin M
64.AN4572019EOXIDATIVE MEDICINE AND CELLULAR LONGEVITY Vol. 2019 (): #3061607 - (14), (DOI: 10.1155/2019/3061607) 2019WOS23181209.0000Modulation of Antioxidant Potential with Coenzyme Q10 Suppressed Invasion of Temozolomide-Resistant Rat Glioma In Vitro and In VivoBuric S, Podolski-Renic A, Dinic J, Stankovic T, Jovanovic M, Hadzic S, Ayuso J, Virumbrales-Muñoz M, Fernández L, Ochoa I, Pérez-García V, Pasic M
65.AN4572019ECURRENT MEDICINAL CHEMISTRY Vol. 26 (33): # 6074 - 6106 (33), (DOI: 10.2174/0929867325666180607094856) 2019WOS47447044.0000Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance TreatmentStankovic T, Dinic J, Podolski-Renic A, Musso L, Buric S, Dallavalle S, Pesic M
66.AN4572019EJOURNAL OF MEDICAL BIOCHEMISTRY Vol. 38 (2): # 188 - 195 (8), (DOI: 10.2478/jomb-2018-0022) APR 2019WOS17157015.0000ASSOCIATION OF OVEREXPRESSED MYC GENE WITH ALTERED PHACTR3 AND E2F4 GENES CONTRIBUTES TO NON-SMALL CELL LUNG CARCINOMA PATHOGENESISDragoj M, Bankovic J, Podolski-Renic A, Buric S, Pesic M, Tanic N, Stankovic T
67.AN4572019EBIOMOLECULES Vol. 9 (10): #616 - (13), (DOI: 10.3390/biom9100616) OCT 2019WOS13111504.2308Parvifloron D from Plectranthus strigosus: Cytotoxicity Screening of Plectranthus spp. ExtractsGarcia C, Ntungwe E, Rebelo A, Bessa C, Stankovic T, Dinic J, Díaz-Lanza A, Reis C, Roberto A, Pereira P, Cebola M, Saraiva L, Pesic M, Duarte N, Rijo P
68.AN4572019ECANCERS Vol. 11 (6): #848 - (20), (DOI: 10.3390/cancers11060848) JUN 2019WOS393620010.0000A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein InhibitorFallacara A, Zamperini C, Podolski-Renic A, Dinic J, Stankovic T, Stepanovic M, Mancini A, Rango E, Iovenitti G, Molinari A, Bugli F, Sanguinetti M, Torelli R, Martini M, Maccari L, Valoti M, Dreassi E, Botta M, Pesic M, Schenone S
69.AN4572019EINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol. 20 (18): #4575 - (21), (DOI: 10.3390/ijms20184575) SEP 2 2019WOS18188015.0000Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer CellsDinic J, Podolski-Renic A, Jovanovic M, Musso L, Tsakovska I, Pajeva I, Dallavalle S, Pesic M
70.AN4572020M21a+EReviewDRUG RESISTANCE UPDATES Vol. 48 (): #100658 - (19), (DOI: 10.1016/j.drup.2019.100658) JAN 2020WOS5351820.000051.0000Advanced technological tools to study multidrug resistance in cancerAndrei L, Kasas S, Garrido I, Stankovic T, Korsnes M, Vaclavikova R, Assaraf Y, Pesic M
71.AN4572020M21aEArticleEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY Vol. 191 (): #112119 - (11), (DOI: 10.1016/j.ejmech.2020.112119) APR 1 2020WOS232398.571416.4286Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: Optimization of potency and evaluation of anticancer potentialJovanovic M, Zhukovsky D, Podolski-Renic A, Zalubovskis R, Dar'in D, Sharoyko V, Tennikova T, Pesic M, Krasavin M
72.AN4572020M21aEArticleACS MEDICINAL CHEMISTRY LETTERS Vol. 11 (5): # 839 - 845 (7), (DOI: 10.1021/acsmedchemlett.9b00642) MAY 14 2020WOS2018126.00009.0000Molecular Docking Studies of Royleanone Diterpenoids from Plectranthus spp. as P-Glycoprotein InhibitorsIsca V, Ferreira R, Garcia C, Monteiro C, Dinic J, Holmstedt S, André V, Pesic M, dos S, Candeias N, Afonso C, Rijo P
73.AN4572020M21aEArticleFRONTIERS IN PHARMACOLOGY Vol. 11 (): #557789 - (10), (DOI: 10.3389/fphar.2020.557789) NOV 17 2020WOS1714174.00004.6667Royleanone Derivatives From Plectranthus spp. as a Novel Class of P-Glycoprotein InhibitorsGarcia C, Isca V, Pereira F, Monteiro C, Ntungwe E, Sousa F, Dinic J, Holmstedt S, Roberto A, Díaz-Lanza A, Reis C, Pesic M, Candeias N, Ferreira R, Duarte N, Afonso C, Rijo P
74.AN4572020M21aEArticleANTIOXIDANTS Vol. 9 (6): #519 - (18), (DOI: 10.3390/antiox9060519) JUN 2020WOS1813135.45455.9091Protoflavone-Chalcone Hybrids Exhibit Enhanced Antitumor Action through Modulating Redox Balance, Depolarizing the Mitochondrial Membrane, and Inhibiting ATR-Dependent SignalingLatif A, Jernei T, Podolski-Renic A, Kuo C, Vágvölgyi M, Girst G, Zupkó I, Develi S, Ulukaya E, Wang H, Pesic M, Csámpai A, Hunyadi A
75.AN4572020M21aEArticleCANCERS Vol. 12 (6): #1570 - (22), (DOI: 10.3390/cancers12061570) JUN 2020WOS181598.571410.7143Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In VivoNesovic M, Rankov A, Podolski-Renic A, Nikolic I, Tasic G, Mancini A, Schenone S, Pesic M, Dinic J
76.AN4572020M21EArticleINVESTIGATIONAL NEW DRUGS Vol. 38 (3): # 584 - 598 (15), (DOI: 10.1007/s10637-019-00803-6) JUN 2020WOS7578.00005.0000CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cellsDinic J, Ríos-Luci C, Karpaviciene I, Cikotiene I, Fernandes M, Pesic M, Padrón J
77.AN4572020M21EArticleFRONTIERS IN MOLECULAR BIOSCIENCES Vol. 7 (): #586146 - (17), (DOI: 10.3389/fmolb.2020.586146) OCT 6 2020WOS211978.000019.0000Novel TrxR1 Inhibitors Show Potential for Glioma Treatment by Suppressing the Invasion and Sensitizing Glioma Cells to ChemotherapyJovanovic M, Dragoj M, Zhukovsky D, Dar'in D, Krasavin M, Pesic M, Podolski-Renic A
78.AN4572020M22EArticleJOURNAL OF MOLECULAR RECOGNITION Vol. 33 (12): #e2849 - (14), (DOI: 10.1002/jmr.2849) DEC 2020WOS2825171.66678.3333A perspective view on the nanomotion detection of living organisms and its featuresVenturelli L, Kohler A, Stupar P, Villalba M, Kalauzi A, Radotic K, Bertacchi M, Dinarelli S, Girasole M, Pesic M, Bankovic J, Vela M, Yantorno O, Willaert R, Dietler G, Longo G, Kasas S
79.AN4572020M22EArticleEUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY Vol. 76 (11): # 1539 - 1546 (8), (DOI: 10.1007/s00228-020-02937-6) NOV 2020WOS5275.00002.0000Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertensionMomcilovic S, Jovanovic A, Radojkovic D, Nikolic V, Jankovic S, Pesic M, Milovanovic J
80.AN4572020M21EEditorial MaterialOXIDATIVE MEDICINE AND CELLULAR LONGEVITY Vol. 2020 (): #2407074 - (3), (DOI: 10.1155/2020/2407074) JUN 3 2020WOS44404.0000Natural Products: Optimizing Cancer Treatment through Modulation of Redox BalanceRijo P, Pesic M, Fernandes A, Santos C
81.AN4572021M21a+EReviewDRUG RESISTANCE UPDATES Vol. 55 (): #100753 - (24), (DOI: 10.1016/j.drup.2021.100753) MAR 2021WOS4330820.000030.0000In vitro biomimetic models for glioblastoma-a promising tool for drug response studiesStankovic T, Randelovic T, Dragoj M, Buric S, Fernández L, Ochoa I, Pérez-García V, Pesic M
82.AN4572021M21aEArticleCANCERS Vol. 13 (21): #5308 - (17), (DOI: 10.3390/cancers13215308) NOV 2021WOS12898.57145.7143New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase InhibitorsPodolski-Renic A, Dinic J, Stankovic T, Tsakovska I, Pajeva I, Tuccinardi T, Botta L, Schenone S, Pesic M
83.AN4572021M21aEArticlePHARMACEUTICS Vol. 13 (6): #825 - (18), (DOI: 10.3390/pharmaceutics13060825) JUN 2021WOS108712.00008.0000Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections TreatmentNeto I, Domínguez-Martín E, Ntungwe E, Reis C, Pesic M, Faustino C, Rijo P
84.AN4572021M21EArticleMEDICINA-LITHUANIA Vol. 57 (5): #446 - (9), (DOI: 10.3390/medicina57050446) MAY 2021WOS8678.00006.0000Nano-Motion Analysis for Rapid and Label Free Assessing of Cancer Cell Sensitivity to ChemotherapeuticsStupar P, Podolski-Renic A, Villalba M, Dragoj M, Stojanov S, Pesic M, Kasas S
85.AN4572021M21EReviewBIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS Vol. 1865 (1): #129759 - (11), (DOI: 10.1016/j.bbagen.2020.129759) JAN 2021WOS4478.00004.0000Protein kinases as targets for developing anticancer agents from marine organismsQiao G, Bi K, Liu J, Cao S, Liu M, Pesic M, Lin X
86.AN4572021M22EArticleBIOLOGIA FUTURA Vol. 72 (2): # 119 - 125 (7), (DOI: 10.1007/s42977-020-00043-3) JUN 2021WOS1165.00001.0000Towards policies that capture the expected value of biomolecular diversity for drug discovery, human health, and well-beingPesic M, Egamberdieva D, Kolodziejczyk B, Elsässer S, Neergheen V, Kagansky A
87.AN4572021M22EArticleJOURNAL OF THE SERBIAN CHEMICAL SOCIETY Vol. 86 (12): # 1219 - 1228 (10), (DOI: 10.2298/JSC210806085K) 2021WOS4375.00003.0000Two new jatrophane diterpenes from the roots of Euphorbia nicaeensisKrstic G, Kostic A, Jadranin M, Pesic M, Novakovic M, Aljancic I, Vajs V
88.AN4572021M22EArticleBRAIN SCIENCES Vol. 11 (7): #884 - (14), (DOI: 10.3390/brainsci11070884) JUL 2021WOS2216103.125010.0000Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma CellsKostic A, Stojanov S, Podolski-Renic A, Nesovic M, Dragoj M, Nikolic I, Tasic G, Schenone S, Pesic M, Dinic J
89.AN4572021M22EArticleBRAIN SCIENCES Vol. 11 (8): #1025 - (12), (DOI: 10.3390/brainsci11081025) AUG 2021WOS161175.000011.0000Development and Validation of a Long-Term 3D Glioblastoma Cell Culture in Alginate Microfibers as a Novel Bio-Mimicking Model System for Preclinical Drug TestingDragoj M, Stojkovska J, Stankovic T, Dinic J, Podolski-Renic A, Obradovic B, Pesic M
90.AN4572021M22ECorrectionBIOLOGIA FUTURA Vol. 72 (2): # 127 - 127 (1), (DOI: 10.1007/s42977-020-00045-1) JUN 2021WOS00600.0000Towards policies that capture the expected value of biomolecular diversity for drug discovery, human health, and well-being (Aug, 10.1007/s42977-020-00043-3, 2020)Pesic M, Egamberdieva D, Kolodziejczyk B, Elsässer S, Neergheen V, Kagansky A
91.AN4572022M21a+EArticleEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY Vol. 228 (): #113980 - (16), (DOI: 10.1016/j.ejmech.2021.113980) JAN 15 2022WOS54720.00004.0000Straightforward access to novel mitochondriotropics derived from 2-arylethanol as potent and selective antiproliferative agentsHicke F, Puerta A, Dinic J, Pesic M, Padrón J, López O, Fernández-Bolaños J
92.AN4572022M21aEArticleACS MEDICINAL CHEMISTRY LETTERS Vol. 13 (4): # 674 - 680 (7), (DOI: 10.1021/acsmedchemlett.1c00711) APR 14 2022WOS111098.57147.1429C20-nor-Abietane and Three Abietane Diterpenoids fromPlectranthus mutabilisLeaves as P-Glycoprotein ModulatorsNtungwe E, Stojanov S, Duarte N, Candeias N, Díaz-Lanza A, Vágvölgyi M, Hunyadi A, Pesic M, Rijo P
93.AN4572022M21EArticleNEURO-ONCOLOGY ADVANCES Vol. 4 (1): #vdac155 - (13), (DOI: 10.1093/noajnl/vdac155) JAN 1 2022WOS94105.00002.5000On optimal temozolomide scheduling for slowly growing glioblastomasSegura-Collar B, Jiménez-Sánchez J, Gargini R, Dragoj M, Sepúlveda-Sánchez J, Pesi M, Ramírez M, Ayala-Hernández L, Sánchez-Gómez P, Pérez-García V
94.AN4572022M21EArticleLIFE-BASEL Vol. 12 (9): #1291 - (14), (DOI: 10.3390/life12091291) SEP 2022WOS7586.66674.1667Decreased TSPAN14 Expression Contributes to NSCLC ProgressionJovanovic M, Stankovic T, Buric S, Bankovic J, Dinic J, Ljujic M, Pesic M, Dragoj M
95.AN4572022M21EArticleLIFE-BASEL Vol. 12 (10): #1503 - (18), (DOI: 10.3390/life12101503) OCT 2022WOS8478.00004.0000Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase InhibitorsStojanov S, Kostic A, Ljujic M, Lupsic E, Schenone S, Pesic M, Dinic J
96.AN4572022M21EReviewFRONTIERS IN MOLECULAR BIOSCIENCES Vol. 9 (): #883297 - (16), (DOI: 10.3389/fmolb.2022.883297) MAY 19 2022WOS442948.000029.0000The Role of the Thioredoxin Detoxification System in Cancer Progression and ResistanceJovanovic M, Podolski-Renic A, Krasavin M, Pesic M
97.AN4572023M21a+EReviewTRENDS IN MOLECULAR MEDICINE Vol. 29 (3): # 173 - 187 (15), (DOI: 10.1016/j.molmed.2022.12.002) MAR 2023WOS2413197.14294.6429Biodiversity: the overlooked source of human healthLinhares Y, Kaganski A, Agyare C, Kurnaz I, Neergheen V, Kolodziejczyk B, Kedra M, Wahajuddin M, El-Youssf L, dela C, Baran Y, Pesic M, Shrestha U, Bakiu R, Allard P, Rybtsov S, Pieri M, Siciliano V, Bueso Y
98.AN4572023M21aEArticleBIOORGANIC CHEMISTRY Vol. 133 (): #106410 - (14), (DOI: 10.1016/j.bioorg.2023.106410) APR 2023WOS135145.00002.0833Biotinylated selenocyanates: Potent and selective cytostatic agentsRoldán-Peña J, Puerta A, Dinic J, Stojanov S, González-Bakker A, Hicke F, Mishra A, Piyasaengthong A, Maya I, Walton J, Pesic M, Padrón J, Fernández-Bolaños J, López O
99.AN4572023M21aEArticleBIOORGANIC CHEMISTRY Vol. 138 (): #106605 - (22), (DOI: 10.1016/j.bioorg.2023.106605) SEP 2023WOS9398.57142.1429Novel hybrids of sclareol and 1,2,4-triazolo[1,5-a]pyrimidine show collateral sensitivity in multidrug-resistant glioblastoma cellsStojkovic P, Kostic A, Lupsic E, Jovanovic N, Novakovic M, Nedialkov P, Trendafilova A, Pesic M, Opsenica I
100.AN4572023M21aEArticlePHARMACEUTICS Vol. 15 (7): #1942 - (14), (DOI: 10.3390/pharmaceutics15071942) JUL 2023WOS31712.00001.0000Coleon U, Isolated from Plectranthus mutabilis Codd., Decreases P-Glycoprotein Activity Due to Mitochondrial InhibitionStojanov S, Ntungwe E, Dinic J, Podolski-Renic A, Pajovic M, Rijo P, Pesic M
101.AN4572023M21EArticleBULLETIN OF MATHEMATICAL BIOLOGY Vol. 85 (1): #8 - (27), (DOI: 10.1007/s11538-022-01113-4) JAN 2023WOS8668.00006.0000Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell PopulationsOrtega-Sabater C, Calvo G, Dinic J, Podolski A, Pesic M, Pérez-García V
102.AN4572023M21EArticleDIAGNOSTICS Vol. 13 (24): #3617 - (18), (DOI: 10.3390/diagnostics13243617) DEC 2023WOS103124.00001.5000Immunofluorescence-Based Assay for High-Throughput Analysis of Multidrug Resistance Markers in Non-Small Cell Lung Carcinoma Patient-Derived CellsDinic J, Podolski-Renic A, Dragoj M, Stojanov S, Stepanovic A, Lupsic E, Pajovic M, Jovanovic M, Rodic D, Maric D, Ercegovac M, Pesic M
103.AN4572023M21EArticlePLANTS-BASEL Vol. 12 (24): #4181 - (22), (DOI: 10.3390/plants12244181) DEC 2023WOS2086.66670.0000LC-ESI QToF MS Non-Targeted Screening of Latex Extracts of Euphorbia seguieriana ssp. seguieriana Necker and Euphorbia cyparissias and Determination of Their Potential Anticancer ActivityJadranin M, Savic D, Lupsic E, Podolski-Renic A, Pesic M, Tesevic V, Milosavljevic S, Krstic G
104.AN4572023M22EArticleNEW JOURNAL OF CHEMISTRY Vol. 47 (14): # 6844 - 6855 (12), (DOI: 10.1039/d3nj00427a) APR 3 2023WOS62103.12501.2500Novel artesunate-pyrimidine-based hybrids with anticancer potential against multidrug-resistant cancer cellsKoracak L, Lupsic E, Jovanovic N, Jovanovic M, Novakovic M, Nedialkov P, Trendafilova A, Zlatovic M, Pesic M, Opsenica I
105.AN4572024M21a+EArticleBIOMEDICINE & PHARMACOTHERAPY Vol. 174 (): #116496 - (19), (DOI: 10.1016/j.biopha.2024.116496) MAY 2024WOS82720.00002.0000Novel hybrid compounds of sclareol and doxorubicin as potential anticancer nanotherapy for glioblastomaStepanovic A, Jovanovic N, Korac A, Zlatovic M, Nikolic I, Opsenica I, Pesic M
106.AN4572024M21a+EReviewBIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER Vol. 1879 (6): #189220 - (12), (DOI: 10.1016/j.bbcan.2024.189220) NOV 2024WOS51820.00001.0000New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomasYao H, Luo L, Li R, Zhao Y, Zhang L, Pesic M, Cai L, Li L
107.AN4572024M21aEArticleBIOORGANIC CHEMISTRY Vol. 145 (): #107168 - (16), (DOI: 10.1016/j.bioorg.2024.107168) APR 2024WOS92174.00000.6667Coumarins-lipophilic cations conjugates: Efficient mitocans targeting carbonic anhydrasesFuentes-Aguilar A, González-Bakker A, Jovanovic M, Stojanov S, Puerta A, Gargano A, Dinic J, Vega-Báez J, Merino-Montiel P, Montiel-Smith S, Alcaro S, Nocentini A, Pesic M, Supuran C, Padrón J, Fernández-Bolaños J, López O
108.AN4572024M21EArticleCANCERS Vol. 16 (11): #1984 - (25), (DOI: 10.3390/cancers16111984) JUN 2024WOS42124.00001.0000Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase InhibitorsDinic J, Dragoj M, Stojanov S, Stepanovic A, Lupsic E, Pajovic M, Mohr T, Glumac S, Maric D, Ercegovac M, Podolski-Renic A, Pesic M
109.AN4572024M21EReviewLIFE-BASEL Vol. 14 (9): #1142 - (33), (DOI: 10.3390/life14091142) SEP 2024WOS2068.00000.0000Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision MedicineDinic J, Stojanov S, Dragoj M, Grozdanic M, Podolski-Renic A, Pesic M
110.AN4572024M21EReviewMOLECULES Vol. 29 (18): #4308 - (32), (DOI: 10.3390/molecules29184308) SEP 2024WOS0068.00000.0000Plant-Based Products Originating from Serbia That Affect P-glycoprotein ActivityDinic J, Podolski-Renic A, Novakovic M, Li L, Opsenica I, Pesic M
111.AN4572024M21aEEditorial MaterialFRONTIERS IN PHARMACOLOGY Vol. 15 (): #1484339 - (3), (DOI: 10.3389/fphar.2024.1484339) SEP 3 2024WOS00400.0000Editorial: Natural products and nanoparticles in cancer treatment: is there a light at the end of the tunnel?Pesic M, Chahardehi A, Echeverria J, Talib W
112.AN4572025EBIOORGANIC CHEMISTRY Vol. 165 (): #108967 - (21), (DOI: 10.1016/j.bioorg.2025.108967) OCT 2025WOS10800.0000Sclareol-based natural nanoparticles with adamantane moieties exert anticancer effects against non-small cell lung carcinoma cellsStojkovic P, Lupsic E, Jovanovic N, Stepanovic A, Nedialkov P, Podolski-Renic A, Pesic M, Opsenica I
113.AN4572025EJOURNAL OF DRUG TARGETING Vol. 33 (3): # 368 - 383 (16), (DOI: 10.1080/1061186X.2024.2427185) MAR 16 2025WOS10900.0000Drug screening approaches for small-molecule compounds in cancer-targeted therapyZhao Y, Yuan C, Shi Y, Liu X, Luo L, Zhang L, Pesic M, Yao H, Li L
114.AN4572025EONCOLOGIE Vol. 27 (5): # 697 - 710 (14), (DOI: 10.1515/oncologie-2025-0228) SEP 24 2025WOS00800.0000Impact of ex vivo cell culturing on ABC transporters' expression and drug sensitivity in patient-derived non-small cell lung cancer modelsDinic J, Stojanov S, Lupsic E, Pajovic M, Stepanovic A, Dragoj M, Podolski-Renic A, Pesic M
115.AN4572025EFRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY Vol. 13 (): #1677261 - (15), (DOI: 10.3389/fcell.2025.1677261) OCT 24 2025WOS001600.0000PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylationGrdovic N, Tolic A, Jovanovic M, Rajic J, Dordevic M, Stojanovic M, Hadzic S, Markovic T, Saric A, Dinic S, Jovanovic J, Mihailovic M, Podolski-Renic A, Pesic M, Vidakovic M, Uskokovic A
116.AN4572025ECURRENT ISSUES IN MOLECULAR BIOLOGY Vol. 47 (4): #281 - (17), (DOI: 10.3390/cimb47040281) APR 17 2025WOS001100.0000Associating Patient Responses with Drug Sensitivity in Non-Small Cell Lung Carcinoma Using an Immunoassay on Patient-Derived Cell CulturesPodolski-Renic A, Stojanov S, Maric D, Dinic J, Dragoj M, Stepanovic A, Lupsic E, Pajovic M, Glumac S, Ercegovac M, Pesic M
117.AN4572025EMOLECULES Vol. 30 (24): #4756 - (22), (DOI: 10.3390/molecules30244756) DEC 12 2025WOS001000.0000Novel Adamantane-Sclareol Hybrids Exploit ROS Vulnerability to Overcome Multidrug-Resistance in Glioblastoma CellsLupsic E, Stojkovic P, Grozdanic M, Terzic-Jovanovic N, Pajovic M, Koutsougianni F, Alexopoulou D, Opsenica I, Pesic M, Podolski-Renic A
118.AN4572025EPHARMACEUTICS Vol. 17 (2): #189 - (23), (DOI: 10.3390/pharmaceutics17020189) FEB 2025WOS10900.0000LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular ModelsPodolski-Renic A, Chigriai M, Stojanov S, Grozdanic M, Lupsic E, Nikolic I, Dragoj M, Dinic J, Pesic M
119.AN4572025EPHARMACEUTICS Vol. 17 (7): #815 - (4), (DOI: 10.3390/pharmaceutics17070815) JUN 24 2025WOS00300.0000Novel Therapeutic Strategies for GlioblastomaPodolski-Renic A, Dinic J, Pesic M
120.AN4572026EBIOORGANIC CHEMISTRY Vol. 168 (): #109307 - (24), (DOI: 10.1016/j.bioorg.2025.109307) JAN 2026WOS001000.0000Novel pyrimidine-artesunate hybrids overcome multidrug-resistance in non-small cell lung carcinoma through collateral sensitivityKoracak L, Ajdacic V, Selakovic M, Pajovid M, Novakovic M, Lupsic E, Podolski-Renic A, Zlatovic M, Pesic M, Opsenica I
121.AN4572026EFUTURE MEDICINAL CHEMISTRY Vol. 18 (1): # 67 - 78 (12), (DOI: 10.1080/17568919.2025.2602963) JAN 2 2026WOS00600.0000Integrative lipophilicity assessment and pharmacokinetic correlation of pyrimidine precursors and artesunate-pyrimidine hybrids: development of QSAR models for anticancer activity and interaction with P-glycoproteinMosic M, Koracak L, Grozdanic M, Jovanovic N, Pesic M, Segan S

27. 04. 2026.; 00:10:03; Trajanje procesiranja: 0.047 s


Legenda:

RB - redni broj rezultata
IBI - identifikacioni broj istraživača
Godina - godina u kojoj je rezultat publikovan (isključivo sa kompletnom paginacijom)
Kat - kategorija rezulata
Tip - tip rezultata (teorijski, simulacioni ili eksperimentalni)
Vrsta - vrsta rezultata
Referenca - referenca rezultata (bez autora i naslova rezultata) sa direktnim linkom na rezultat (ako ima DOI broj), sa linkom na zapis u eNauci ili WOS
TC - ukupan broj citata rezulata na dan 31. 1. 2026. godine
TCP - ukupan broj citata rezultata u periodu 2015-2024
BA - broj autora na rezultatu
NBB - normirani broj bodova rezultata
NTC - normirani broj citata rezultata u periodu 2015-2024
Naslov - naslov rezultata
Autori - spisak svih autora ili najviše prvih 30 autora


Primer:

Primer normiranja broja M poena i broja citata ostvarenih na jednom rezultatu: eksperimentalni rad sa 11 autora u časopisu kategorije M21a+ koji je publikovan 2020. godine, citiran je 65 puta, od čega 55 puta u periodu 2015-2024. godine.

Normirani broj M poena koje istraživač ostvaruje na rezultatu je 20/(1+0.2*(11-10))=16.6667 a normirani broj citata je 55/(1+0.2*(11-10))=45.8333.

Ukupan broj ostaverinih bodova utvrđuje se na naznačenom periodu za sabiranje normiranih M poena svakog istraživača i u periodu za određivanje ukupnog broja normiranih citata (2015-2024).